A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorVasileios Kalles

About this trial

This study aims to learn whether a handheld robotic device, called the HandX, can help surgeons safely perform a minimally invasive nipple-sparing mastectomy. This type of mastectomy uses a small incision at the side of the breast to remove breast tissue while keeping the skin and nipple in place. The goal is to lower scarring, improve comfort, and support good cosmetic results after surgery.

Participants in this study will already be planning to have a therapeutic or preventive mastectomy with immediate implant-based reconstruction. All surgeries are done at Mediterraneo Hospital in Greece.

During the operation, surgeons use the HandX device to assist with the endoscopic dissection. Researchers will collect information about how long the surgery takes, whether the planned approach can be completed without switching to open surgery, and whether any surgical complications occur. They will also check healing, infection, and implant-related problems for up to 365 days after surgery. Participants will complete the BREAST-Q questionnaire before surgery and at several times after surgery to share their views on comfort, well-being, and cosmetic outcomes.

About 15 participants will take part. The results will help researchers understand whether this approach is practical and safe, and whether it should be studied further in a larger trial.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female sex

Age ≥ 18 years old

early invasive breast cancer (Clinical Stage I-II at diagnosis) undergoing primary surgery

early invasive breast cancer (Clinical Stage I-II at diagnosis) undergoing surgery post systemic (neoadjuvant) therapy with clinical evidence of partial or complete response

Disqualifiers

Chest wall or skin invasion

Extended lymph node involvement at diagnosis (cN2)

Inflammatory breast cancer

Tumor distance from nipple - areola complex <1cm on imaging studies

Trial design

Design model

Single group

Treatments tested in this trial

  • Endoscopic nipple sparing mastectomy

    Procedure/Surgery

    A minimally invasive nipple-sparing mastectomy performed through a single lateral mammary fold incision using endoscopic visualization and CO₂ insufflation. Breast tissue is dissected from the skin envelope and nipple-areola complex, and immediate implant-based reconstruction is performed according to standard practice. The HandX device is used for articulating endoscopic dissection.

  • HandX endoscopic instrument

    Device

    A handheld articulating endoscopic instrument used to assist with endoscopic dissection during nipple-sparing mastectomy. The HandX device provides wrist-like articulation, motion scaling, and ergonomic control during minimally invasive surgery.

Treatment groups

15 Participants
are divided into 1 treatment group
Group A: HandX-assisted endoscopic nipple sparing mastectomyExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Technical success

Completion of the planned procedure via the minimally invasive approach without unplanned conversion.

Time frame
Intraoperative (Day 0)
2

Surgical Safety

Major (Clavien-Dindo ≥III) complications

Time frame
Postoperative Day 0-30

Secondary outcomes

1

Operative Time

Total Operative Time

Time frame
Intraoperative (Day 0)
2

Blood Loss

Intraoperative Blood Loss

Time frame
Intraoperative (Day 0)
3

Length of Stay

Length of hospital stay in days

Time frame
From hospitalization to discharge (average 1-3 days)
4

Complications

30-day complication rate (Clavien-Dindo)

Time frame
Within 30 days after surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Vasileios Kalles

Lead sponsor

Mediterraneo Hospital

Sponsor institution